#South Korea #GC Biopharma #Yongin #Varicella Vaccine #MAV/06

GC Biopharma's Groundbreaking Review on MAV/06 Varicella Vaccine

GC Biopharma, a prominent biopharmaceutical company in South Korea, has unveiled a landmark review paper that encapsulates three decades of extensive research on its proprietary varicella vaccine strain, known as MAV/06. This research was published in the esteemed journal, Human Vaccines & Immunotherapeutics, and highlights the vaccine’s safety, immunogenicity, and effectiveness in comparison to global standards, especially the Oka strain vaccine.

A Collaborative Effort

The publication is a result of collaboration between GC Biopharma and researchers from both Ajou University and Sungkyunkwan University. The research team systematically analyzed over 40 studies which spanned clinical trial results and real-world data collected from 1991 to 2023. This extensive investigation included safety reports and genomic analyses that emphasize the MAV/06 strain's unique genetic alignment with established vaccines.

MAV/06: Key Findings

It was found that while MAV/06 belongs to the same clade (Clade 2) as the globally recognized Oka-derived vaccines, it possesses distinguishing features that affirm its safety profile. Notably, MAV/06 demonstrated a broad immune response, offering significant protection not only against Clade 2 variations but also against multiple other clades (1, 3, and 5) and wild-type strains of the varicella virus.

The clinical findings are particularly impressive: the vaccine successfully elicited neutralizing antibodies in 99% to 100% of vaccinated individuals, sustaining levels comparable to those achieved with the Oka strain vaccine. Importantly, a thorough analysis of the adverse events reported over the past 30 years revealed an incidence rate of 0.41 to 0.57 cases per 100,000 doses, which is substantially lower than that observed with many other global vaccines.

GC Biopharma’s second varicella vaccine, BARYCELA Inj., is particularly noteworthy as it became the first varicella vaccine worldwide to be produced without any antibiotics, thus minimizing the risk of allergic reactions related to antibiotics commonly used in the manufacturing process.

Global Impact and Future Directions

To date, over 30 million doses of the MAV/06-based vaccines have been distributed across more than 20 countries. Furthermore, BARYCELA Inj. received the World Health Organization (WHO) Pre-Qualification (PQ) certification in 2023, thereby enhancing its market competitiveness and global accessibility. With the WHO's acceptance of its interchangeability with Oka strain vaccines, the utilization of GC Biopharma's products in the global market is set to expand significantly.

Bong-kyoo Choi, the Head of the AI Data Science Center at GC Biopharma stated, "This review paper is significant in that it academically compiles the safety and effectiveness that the Korean varicella vaccine has proven in the global market over the past 30 years. We will continue to contribute to fostering child health globally, particularly in regions with limited vaccine access."

About GC Biopharma

Established over half a century ago, GC Biopharma (previously Green Cross Corporation) is headquartered in Yongin, South Korea. The company specializes in the development and manufacturing of plasma-derived products and vaccines. As part of its mission to meet the healthcare demands of the future, GC Biopharma continues to innovate through its robust research and development capabilities, focusing on protein engineering, mRNA technologies, and lipid nanoparticle drug delivery systems.

For more information about the company and its initiatives, visit GC Biopharma's website.